- Home
- NDLS vs UBX Comparison
NDLS vs UBX Comparison
Compare NDLS & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- UBX
- Stock Information
- Founded
- NDLS 1995
- UBX 2009
- Country
- NDLS United States
- UBX United States
- Employees
- NDLS N/A
- UBX N/A
- Industry
- NDLS Restaurants
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- UBX Health Care
- Exchange
- NDLS Nasdaq
- UBX Nasdaq
- Market Cap
- NDLS 35.4M
- UBX 13.9M
- IPO Year
- NDLS 2013
- UBX 2018
- Fundamental
- Price
- NDLS $0.72
- UBX $0.78
- Analyst Decision
- NDLS Strong Buy
- UBX Strong Buy
- Analyst Count
- NDLS 2
- UBX 3
- Target Price
- NDLS $3.00
- UBX $4.67
- AVG Volume (30 Days)
- NDLS 198.4K
- UBX 609.1K
- Earning Date
- NDLS 08-06-2025
- UBX 08-05-2025
- Dividend Yield
- NDLS N/A
- UBX N/A
- EPS Growth
- NDLS N/A
- UBX N/A
- EPS
- NDLS N/A
- UBX N/A
- Revenue
- NDLS $495,670,000.00
- UBX N/A
- Revenue This Year
- NDLS $5.37
- UBX N/A
- Revenue Next Year
- NDLS $0.68
- UBX N/A
- P/E Ratio
- NDLS N/A
- UBX N/A
- Revenue Growth
- NDLS N/A
- UBX N/A
- 52 Week Low
- NDLS $0.55
- UBX $0.36
- 52 Week High
- NDLS $1.83
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- NDLS 36.25
- UBX 48.12
- Support Level
- NDLS $0.76
- UBX $0.67
- Resistance Level
- NDLS $0.82
- UBX $0.83
- Average True Range (ATR)
- NDLS 0.06
- UBX 0.09
- MACD
- NDLS -0.00
- UBX 0.01
- Stochastic Oscillator
- NDLS 4.80
- UBX 24.67
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.